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The prion protein (PrP) is a Cu2 binding cell surface
glycoprotein that can misfold into a -sheet-rich confor-
mation to cause prion diseases. The majority of copper
binding studies have concentrated on the octarepeat
region of PrP. However, using a range of spectroscopic
techniques, we show that copper binds preferentially to
an unstructured region of PrP between residues 90 and
115, outside of the octarepeat domain. Comparison of
recombinant PrP with PrP-(91–115) indicates that this
prion fragment is a good model for Cu2 binding to the
full-length protein. In contrast to previous reports we
show that Cu2 binds to this region of PrP with a nano-
molar dissociation constant. NMR and EPR spectros-
copy indicate a square-planar or square-pyramidal Cu2
coordination utilizing histidine residues. Studies with
PrP analogues show that the high affinity site requires
both His96 and His111 as Cu2 ligands, rather than a
complex centered on His96 as has been previously sug-
gested. Our circular dichroism studies indicate a loss of
irregular structure on copper coordination with an in-
crease in -sheet conformation. It has been shown that
this unstructured region, between residues 90 and 120,
is vital for prion propagation and different strains of
prion disease have been linked with copper binding. The
role of Cu2 in prion misfolding and disease must now
be re-evaluated in the light of these findings.
Prion diseases are fatal neurodegenerative diseases that in-
clude Creutzfeldt-Jacob disease in humans, mad cow disease in
cattle, and scrapie in sheep. The infectious agent in transmis-
sible spongiform encephalopathies is a proteinous infectious
particle or “prion,” which is devoid of nucleic acid. It is believed
that these spongiform encephalopathies are caused by the ac-
cumulation of an abnormally folded isoform of the cellular
prion protein (PrPC).1 This misfolded protein is rich in -sheet
and is designated the scrapie isoform, PrPSc (1–3).
Whereas normal physiological function of the prion protein is
yet to be determined, the ability of PrPC to bind Cu2 in vivo
and in vitro suggests a role in copper homeostasis (4, 5). Indeed,
elevated copper levels promote endocytosis of PrPC suggesting
that PrP could transport copper into the cell (6, 7). Recent data
has shown that PrPC expression increased the binding of cop-
per to the outer plasma cell membrane and increases antioxi-
dant enzyme activities (8). Furthermore, it is suggested that
PrPC plays a protective role by binding Cu2 in a redox inactive
state (9, 10). An enzymatic role for copper-PrP is also proposed
as it exhibits superoxide dismutase activity (11–14).
The cellular prion protein is a cell surface glycoprotein teth-
ered via a glycosylphosphatidylinositol anchor at the C termi-
nus. There are now a number of NMR solution structures of
mammalian PrPs in the copper-free form (15–18). A crystal
structure of PrPC has also been published. The structure is
dimeric involving domain swapping between monomeric forms
(19). Structurally, PrPC contains two distinct regions. In the
absence of Cu2, the N-terminal domain, residues 23–120, is
unstructured (17) and has a high degree of main chain flexibil-
ity in the absence of copper (20). In contrast, the C-terminal
domain, residues 121–231, is largely -helical (15). Residues
60–91 consist of an octapeptide sequence, PHGGGWGQ, which
is repeated four times. It is this unstructured region that binds
four Cu2 ions cooperatively (5). Although binding of a fifth
Cu2 ion to PrP has been noted (4, 21, 22), as well as Cu2
coordination to a C-terminal fragment of PrP (23). The majority
of studies have concentrated on characterizing the four copper
ions binding to the octarepeat region of PrP. Recent publica-
tions on copper binding to the octarepeats include circular
dichroism (CD) studies (24), electron paramagnetic resonance
spectroscopy (EPR) studies (25), and a crystallographic study
(26). Dissociation constants for Cu2 binding to the octarepeat
region have been reported to be between 1 nM and 10 M (21,
24) although others have suggested a much higher affinity with
a Kd in the femtomolar range (22).
Studies with transgenic mice have shown that mice express-
ing a truncated version of PrP with the octarepeat region
removed are still susceptible to prion infection (27). This has
meant that a direct link between copper and prion disease was
thought to be unlikely. However, recent studies suggest copper
can bind to the unstructured domain of PrP outside of the
octarepeat region with a femtomolar dissociation constant (22).
Residues His111 and/or His96 have been implicated in this bind-
ing (22, 28, 29). Interestingly, the unstructured region between
the N-terminal domain and the structured C-terminal domain
is considered to be essential for amyloid formation and infec-
tivity in prion disease (30–33). Residues in this unstructured
region are thought to play a pivotal role in the misfolding of
* This work was supported in part by Biochemical and Biophysical
Sciences Research Council (BBSRC) Project grants and a University of
London Central Research Fund equipment grant. The costs of publica-
tion of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org)
contains supplemental material.
§ Recipient of a C. J. Martin Postdoctoral Fellowship from the Na-
tional Health and Medical Research Council, Australia.
 Supported by a Senior Fellowship from the BBSRC.
** To whom correspondence should be addressed. Tel.: 44-020-7882-
3054; Fax: 44-020-8983-0973; E-mail: j.viles@qmul.ac.uk.
1 The abbreviations used are: PrPC, cellular isoform of prion pro-
tein; PrP, prion protein; PrPSc, scrapie isoform of prion protein;
TOCSY, total correlation spectroscopy; NOESY, nuclear Overhauser
exchange spectroscopy.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 31, Issue of July 30, pp. 32018–32027, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org32018
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
PrPC into the -sheet-rich conformation (34). The presence of a
high affinity Cu2 site within the region 90–126 should have
profound implications for the copper loaded structure in this
region of PrPC. Cu2 can convert the cellular prion protein into
a protease-resistant species (35). Copper induced structuring in
this region might also explain the different protease resistance
profiles of PrP observed with and without the presence of Cu2
(36), these protease profiles correspond to similar profiles seen
in different strains of prion disease (37). In addition, a frag-
ment from this unstructured region, PrP-(106–126), contains a
hydrophobic cluster of residues and has been shown to be
neurotoxic in both the soluble and fibrillar states (33, 38).
Copper binding to this peptide has been linked with its toxicity
(39).
Metal imbalances are a feature of prion disease (40) and
metal binding to the prion protein is altered in human prion
disease (41). Therefore, it has been suggested that a loss of PrP
function in copper transport and homeostasis may well be a
feature of prion disease. Recent studies have shown that
scrapie infection modulates copper content at a cellular level
(42) and that copper-catalyzed redox damage of PrP is impli-
cated in prion disease (43, 44). Elimination of the copper bind-
ing octarepeat region has been shown to slow disease progres-
sion (27). Additionally, a recent study shows that disease
progression in infected mice is slowed with the use of copper
specific chelation therapy (45). A mutant form of PrP associ-
ated with familial prion disease contains nine additional oct-
arepeats and fails to undergo copper-mediated endocytosis (7).
The role of copper in the normal function of PrP, as well as in
prion diseases, has been the subject of a number of reviews
(46–50).
The aim of this study is to characterize the binding of Cu2
to the unstructured region of PrP outside of the octarepeats.
This region is of particular interest because it is essential for
amyloidogenesis, and metal occupancy confers strain type in
disease. There are some inconsistencies in the literature that
we hope to resolve. For example, the coordinating ligands of
this so-called fifth Cu2 binding site are disputed with an EPR
study, suggesting only His96 as the locus for Cu2 coordination
(29), whereas an EXAFS study suggested His111, Met112, and
His96 as coordinating ligands (28). In addition, the reported
affinities for Cu2 also vary greatly in the literature between
the micromolar (4, 21) and femtomolar (22) dissociation con-
stants. PrP-(23–231) with the octarepeat domain deleted, frag-
ments PrP-(91–115) and PrP-(90–126) and PrP-(91–115) ana-
logues (H96A and H111A) have been used to identify key
residues in Cu2 coordination. We use direct spectroscopic
methods including CD, NMR, and EPR to study the folding,
affinity, coordination geometry, stoichiometry, and pH depend-
ence of copper binding to the prion protein.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant Mouse Prion PrP(23–
23151–90) Protein—The coding region of the full-length mouse PrP-
(23–231) with a deleted octapeptide region, named PrP(23–23151–90),
was cloned into a pET-23 vector to produce a tag-free protein as previ-
ously described (11). The protein was expressed in 2-liter flasks of
Escherichia coli BL21(DE3) cells. Cultures were grown at 37 °C to an
A600 of 0.7 and the protein expression was induced by the addition of
isopropyl--D-thiogalactopyranoside to 1 mM. Bacterial pellets were
harvested after 3 h and sonicated in a buffer containing 8 M urea, 200
mM NaCl, and 50 mM Tris, pH 7.6. The resulting solution was cleared of
bacterial debris by centrifugation at 15,000 rpm for 15 min. The protein
was absorbed to a copper-charged metal affinity column made from
chelating Sepharose (Amersham Biosciences). The protein was eluted
from the column using imidazole (300 mM). The purity of the protein
was checked by polyacrylamide electrophoresis and Coomassie stain-
ing. The protein was refolded by successive rounds of dilution in dis-
tilled water, concentrated using vivaspin concentrator (Vivascience),
and dialyzed with a 12,000–14,000 molecular weight cut-off dialysis
tube at 4 °C against water overnight to remove residual urea. The
concentration of PrP(23–23151–90) was measured by its absorbance
at 280 nm (A280 nm
1 mg/ml, 1 cm,  1.758).
Peptide Synthesis and Purification—Peptides representing various
fragments of PrP were synthesized employing solid phase Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry (A.B.C, Imperial College, London).
After removing from the resin and de-protection, the samples were puri-
fied using reverse phase high performance liquid chromatography and
characterized using mass spectrometry. To mimic the peptides within the
full-length prion protein, all peptides were blocked at the N terminus with
N-acetyl and ethyl ester at the C terminus. One and two-dimensional 1H
NMR spectroscopy confirmed the amino acid sequence.
Design of Peptides—Peptides synthesized included: human (PrP)
sequence, PrP-(91–115), acetyl-QGGGTHSQWNKPSKPKTNMKHM-
AGA; PrP-(90–126), acetyl-GQGGGTHSQWNKPSKPKTNMKHMAG-
AAAAGAVVGGLG; PrP(H96A), acetyl-QGGGTASQWNKPSKPKTNM-
KHMAGA; PrP(H111A), acetyl-QGGGTHSQWN KPSKPKTNMKAM-
AGA; PrP-(58 –91), PrP(4octa), acetyl-GQPHGGGWGQPHGG-
GWGQPHGGGWGQPHGGGWGQ.
Titrations—The pH was measured before and after each spectrum
was recorded. Unless otherwise noted, all titrations were carried out in
the absence of buffers or salts. For all titrations the pH was adjusted
using small aliquots of 100 mM NaOH or HCl. The peptide concentra-
tions were determined using extinction coefficients at 280 nm. An
extinction coefficient of 5690 M1 cm1 (multiplied by the number of
tryptophan residues) was used for each peptide (51). The freeze-dried
peptides contained 20–30% moisture by weight. The addition of metal
ions (CuCl22H2O) or competing ligands was performed using small
aliquots from freshly prepared stock aqueous solutions.
Stability Constants—The absolute affinity (pH independent) of L-His
for Cu2 is 1.5  1010 M1, the apparent affinity, at pH 7.4 is therefore
2.6  108 M1 or a dissociation constant of 3.7 nM (as log   pKa, pH 
9.17–7.4  1.77, and log K1(app)  log K1  log   10.2–1.77  8.43 or
2.6  108 M1). The glycine dissociation constant at pH 7.5 is 500 nM
(52).
Circular Dichroism (CD)—CD spectra were recorded on an AVIV 202
instrument at 25 °C. Typically a cell with a 0.1-cm path length was used
for spectra recorded between 185 and 260 nm with sampling points
every 0.5 nm. A 1-cm path length cell was used for data between 300
and 800 nm with a 2-nm sampling interval. A minimum of three scans
was recorded and the baseline or apospectra were subtracted from each
spectrum. Data were smoothed when necessary. Data were processed
using Microsoft Excel and the KaleidaGraph spread sheet/graph pack-
age. The direct CD measurements (, in mdeg) were converted to molar
ellipticity,  (M1 cm1) using the relationship   /33,000  c  l 
[]/3,300, where []  /cl, c is the concentration, and l the path length.
The molar ellipticity [] is in units of degree cm2 dmol1, therefore, []
{mdeg}/{(10)  (mol liter1)  (cm)}.
Absorption Spectroscopy (UV-Visible)—UV-visible electronic absorp-
tion spectra were obtained with a Hitachi U-3010 double beam spectro-
photometer, using a 1-cm path length.
Nuclear Magnetic Resonance (NMR)—All NMR spectra were ac-
quired on a Bruker Advance 600 MHz spectrometer using a 5-mm
inverse detection (1H), triple-resonance, z-gradient probe. Peptide sam-
ples were prepared in 90% H2O, 10% D2O or 100% D2O, pH 6.5, or for
the Cu2 titrations, pH 7.5, and spectra were acquired at 303 K. In the
90% H2O, 10% D2O samples water suppression was achieved using the
W5 Watergate method (53), whereas samples in 100% D2O had residual
water suppressed with a low power presaturation pulse. For two-di-
mensional spectra, quadrature detection in the indirect dimension was
achieved using the States-TPPI method. Two-dimensional total corre-
lation spectroscopy (TOCSY) spectra were typically acquired with
2048[F2]  512[F1] complex points, with water suppression achieved
using the W5 Watergate sequence. The TOCSY experiment employed a
DIPSI2 sequence for isotropic mixing, with a mixing time of 75 ms (54).
Nuclear Overhauser exchange spectroscopy (NOESY) spectra (55) were
acquired with 2048[F2]  512[F1] data points, with mixing times of
200, 300, and 500 ms. Prior to Fourier transformation, sine-squared
window functions, phase shifted by 90° were applied to both dimen-
sions, the F1 dimension was forward linear predicted to 512 real points
and both dimensions zero filled to 2048 real points. Data were processed
using XWINNMR (Bruker) software running on a SGI O2 work station
and analyzed using the program XEASY (56). Proton resonance assign-
ments and sequential connectivities for PrP-(91–115) were obtained
using the TOCSY and NOESY data and standard homonuclear tech-
niques (57). Analysis of spectra of the H96A and H111A mutants
allowed unambiguous assignment of histidine resonance.
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Electron Paramagnetic Resonance (EPR)—X-band EPR spectra were
acquired on a Bruker Elexsys E500 spectrometer operating at a micro-
wave frequency of 9.38 GHz. The spectra were acquired over a sweep
width of 2500 gauss, a microwave power of 0.63 milliwatt, a modulation
frequency of 10 gauss, and a temperature of either 20 or 100 K. At least
two scans were acquired per sample. The pH of the peptide samples was
adjusted prior to freezing, however, the pH values noted are not altered
to take into account freezing effects.
RESULTS
Cu2 Addition Induces -Sheet Conformation
CD spectra of PrP-(91–115) in the UV region are shown in
Fig. 1. In the absence of copper, PrP-(91–115) gives an predom-
inately random coil CD spectrum in agreement with the struc-
ture of full-length PrP in this region (17). Fig. 1 shows that
addition of Cu2 increases the negative chirality centered at
217 nm with a decrease in the negative CD band at 200 nm.
An isodichroic point is observed at 207 nm with Cu2 addition
indicating a single mode of binding up to 1 eq of copper. The
changes in the CD spectra with Cu2 additions are more ap-
parent by obtaining the difference spectra shown as an insert.
The changes in the CD spectra upon copper coordination indi-
cate an increase in -sheet or extended conformation, accom-
panied by a loss of irregular structure. A similar titration with
Cu2 and PrP-(90–126), at pH 7.5, produces identical UV-CD
spectra (data not shown). Copper binding to His111 and His96
(14 residues apart) are possible candidates as coordinating
ligands and would cause the polypeptide chain to fold back on
itself, perhaps inducing anti-parallel -sheet in this region, the
CD spectra shown in Fig. 1 support this possibility. We show
later that Cu2 does indeed coordinate to both His111 and
His96. The Cu-PrP-(91–115) CD data indicates that the copper-
loaded peptide still possesses a considerable irregular struc-
ture, hence a stable well defined anti-parallel -sheet between
His111 and His96 is unlikely.
pH Dependence of Cu2 Binding
Using visible absorption bands and associated CD bands we
have monitored the pH dependence of Cu2 binding to the prion
protein fragment, PrP-(91–115). PrP-(91–115) was loaded with 1
mol eq of Cu2 and the visible absorption spectrum were ac-
quired at a number of pH values between pH 5.5 and 9.4. Fig. 2,
panel A, shows the resulting overlaid spectra. At pH 5.5, a single
absorption band is apparent at 610 nm corresponding to Cu2 d-d
electronic transitions. As the pH increases the absorption in-
creases in intensity until pH 9. Above pH 6.5 there is a shift in
the absorption maximum from 610 to 540 nm, suggesting a
change in the coordination environment of the Cu2 ion. The
absorption maximum and extinction coefficient (between 40 and
100 M1 cm1) for the Cu-PrP-(91–115) complex are typical for a
type II Cu2 complex. The absorption maximum can be sensitive
to ligand type. For example, using model peptide complexes of
type II copper complexes the wavelength maximum decreases
from 765 nm for Cu2 with a single nitrogen ligand (and three
water oxygens) to 540 nm for Cu2 with four nitrogen ligands
(58). The visible absorption spectra observed here are character-
istic of three or four nitrogen coordinations in a type II square-
planar arrangement.
Circular dichroism spectra of Cu1PrP-(91–115) (1 mol eq of
Cu2 loaded) have been obtained at pH 6.2, 7.2, and 9.2, shown
in Fig. 2B. These data show that the arrangement of ligands
coordinating the Cu2 ions changes significantly with pH. The
CD spectrum at pH 6.2 gives a maximum CD band at 520 nm
and no ellipticity at 580 nm. In direct contrast, at pH 9.2 a
maximal negative CD band at 580 nm is observed with nega-
tive ellipticity at 520 nm. The spectrum at pH 7.2 is a mixture
of the CD spectra from the mildly acidic and basic conditions. A
weighted average of the pH 6.2 and 9.2 spectra shows good
agreement with the pH 7.5 spectra using a 70:30% ratio of pH
6.2 and 9.2, respectively. Addition of 2 eq of Cu2 shows further
changes in the spectra at all three pH values as shown in
Fig. 2C.
Copper coordination to PrP-(91–115) is very sensitive to pH.
The titratable imidazole side chain of histidine provides a ra-
tionale for the pH dependence of binding. The  of the d-d
transition CD bands indicate a strong vicinal effect from the
FIG. 1. Cu2 titration of PrP-(91–115) monitored by CD in the
UV region. 0.085 mM PrP-(91–115), pH 8.4, was titrated with 0.25 mol
eq of Cu2. The spectra show an increase in the negative ellipticity ()
at 217 nm. The inset shows the difference spectra after subtraction of
the apo-PrP-(91–115) spectra.
FIG. 2. pH dependence of Cu2 binding to PrP-(91–115). Panel
A, UV-visible spectra of 0.63 mM PrP-(91–115) with 1 mol eq of Cu2 as
the pH was incremented from pH 5.5 to 9.4. Panels B and C, effect of pH
on PrP-(91–115) as monitored by CD with 1 and 2 eq of Cu2 added,
respectively. Spectra were acquired with 0.3 mM peptide at pH 6.2,
7.2, and 9.2.
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chiral C, this implies main chain coordination via the car-
bonyl or amide (59). The change in coordination geometry and
ligands as the pH is raised above the pKa of histidine is likely
to be because of the additional coordination of main chain
amides as the pH is raised (60).
Cu2 Stoichiometry
To determine the copper binding stoichiometry of PrP-(91–
115), increasing amounts of Cu2 were added to each peptide
and the visible electronic absorption and accompanying CD
bands were monitored. The absorption spectra of Cu2 binding
to PrP-(91–115) at pH 9.2 is shown in Fig. 3. The absorption
band at 540 nm increases until 2 eq of Cu2 have been added.
Beyond 2 eq the spectra display a red shift of the 540 nm peak
(to 560 nm at 3 eq) and a significant increase in intensity of the
charge transfer band observed below 400 nm.
The Fig. 3, inset, shows the mole equivalents of Cu2 added
as a function of the absorbance intensity at pH 9.2, 7.5, and 6.0.
At pH 7.5 there is a discontinuity in the binding curve at 1 mol
eq of Cu2 indicating that the Cu2 ions load onto PrP sequen-
tially. The discontinuity at 1 eq of Cu2 also indicates that
there is a significant difference in the affinity between the
loading of the first and second Cu2 ion. There is a second
discontinuity in the binding curve at 2 eq of Cu2, this is also
observed at pH 9.2 where the absorption peak plateaus at two
Cu2 ions. In contrast, at pH 6.2 the absorption saturates soon
after 1 mol eq of Cu2 is added.
The titrations described above were also carried out using
circular dichroism at pH 6.3 and 9.2 and the CD spectra were
acquired between 300 and 800 nm. Fig. 4, panel A, shows the
pH 9.2 titration, whereas panel B shows binding curves at
various specific wavelengths. Likewise, the CD spectra at pH
6.3 are shown in Fig. 4, panel C, and the accompanying binding
curves in panel D. The binding curves at pH 9.2 (Fig. 4B) show
that the CD bands at 322 and 490 nm have abrupt discontinui-
ties after 1 mol eq of Cu2 is added. After 1 eq of Cu2 there is
a shift in the isodichroic point at 620 nm. In agreement with
the visible absorption spectra at pH 7.5 (Fig. 3, inset) it is clear
that Cu2 binds to PrP sequentially. Finally, there is a second
discontinuity in the 490 nm binding curve at 2 eq of copper,
whereas the negative CD band at 580 nm continues to increase
in intensity beyond 2 eq of Cu2, suggesting further weaker
Cu2 binding to PrP. At pH 6.2 (Fig. 4, panel C) the isodichroic
points at 580 and 310 nm remain unchanged between 1 and 2
eq of Cu2, suggesting that there is a single binding site that
saturates only when excess Cu2 is added.
It is clear from the data described in Figs. 3 and 4 that
binding of Cu2 to PrP-(91–115) does not complete after 1 or
even 2 mol eq additions of copper, as further additions of Cu2
result in further increases in absorbance and CD bands. These
bands are not because of free Cu2 ions in solution, as copper
free in solution is CD silent and gives a absorption band max-
imum at 800 nm, which is not observed. In an attempt to
differentiate weak Cu2 binding to PrP-(91–115) from the
higher affinity Cu2 binding sites, the prion fragment has been
studied (at pH 7.4) in the presence of competing imidazole.
Imidazole is a non-chiral molecule and copper-imidazole does
not give a CD signal in the visible region (data not shown). In
the presence of excess (10 mM) imidazole the CD spectrum of
PrP-(91–115) with 4 eq of Cu2, pH 7.4, looks very similar to
the CD spectra of PrP after only 1 eq of copper is added (see
Supplementary Materials). This suggests that at pH 7.4 only
one copper ion binds to PrP with a significantly higher affinity
than imidazole, as even after 4 eq of Cu2 are added in the
presence of excess imidazole the spectra appear similar to a
single copper bound to PrP-(91–115).
Copper Affinity: Glycine and L-Histidine Competition
The affinity of Cu2 binding to PrP-(91–115) is key to its
physiological significance. To investigate the affinity of Cu2
binding to PrP-(91–115) we have used glycine as a copper
competitor. Two glycine molecules can bind to one Cu2 with
Ka of 1.2  10
8 via both the amino and carboxylate groups (52).
The resulting Cu(Gly)2 visible absorption bands are CD si-
lent. Fig. 5, panel A, shows the visible region CD spectra for
PrP-(91–115) at pH 9.2 as the peptide is titrated to 2 mol eq
of Cu2. A similar competition experiment was also carried
out at pH 7.5. The spectra exhibit a number of bands because
of d-d electronic absorptions, with major peaks at 580 and
688 nm. If glycine was able to successfully compete with
PrP-(91–115) for Cu2 ions, then 4 mol eq of glycine would be
sufficient to remove both Cu2 ions from the peptide. Fig. 5,
panel A, clearly shows that even at double the required
amount of glycine only a single copper has been abstracted.
FIG. 3. Cu2 titration of PrP-(91–115) by UV-visible spectros-
copy. Cu2 was added in 0.25 mol eq relative to PrP-(91–115) (0.32 mM)
at pH 9.2. The spectra corresponding to 1 and 2 mol eq of Cu2 are
highlighted. The inset shows the maximum absorption at 550, pH 9.2;
590, pH 7.5; and 610 nm, pH 6.0, as a function of mole equivalents of
Cu2. The left y axis shows the absorbance as extinction coefficients for
pH 9.2 data, whereas the right y axis shows the extinction coefficients
for pH 6.0 and 7.5.
FIG. 4. CD monitoring of Cu2 binding to PrP-(91–115). Panels A
and C show 0.25 mol eq additions of Cu2 to PrP-(91–115) at pH 9.2,
0.56 mM; and pH 6.3, 0.70 mM, respectively. The spectra corresponding
to 1 and 2 mol eq of Cu2 are highlighted. Panels B and D show the
binding curves at various wavelengths plotted as a function of mole
equivalents of Cu2 added at pH 9.2 and 6.3, respectively.
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Similarly, at pH 7.5 after 8 mol eq of glycine (relative to
peptide) has been added, only a single copper has been ab-
stracted from Cu2PrP-(91–115). Furthermore, only approxi-
mately half of a mole equivalent of copper has been removed
from the weaker affinity copper site with 4 eq of glycine. This
implies that the low affinity site has a Ka comparable with,
but not less than, that of glycine. With 12 mol eq of glycine
the CD band at 480 nm gives the same intensity as is ob-
served with 1 mol eq of Cu2. It appears that the higher
affinity site binds to copper at least an order of magnitude
higher in affinity than the Cu2-glycine complex.
In a similar study, free L-histidine was used to compete for
Cu2 ions. Fig. 5, panel B, shows the effect of adding increasing
amounts of L-His to Cu2PrP-(91–115) at pH 9.2. Histidine has
a Kd for Cu
2 of 0.1 nm at pH 9.2 and 3 nM at pH 7.4 (52).
Unlike Cu(Gly)2, Cu(His)2 is not CD silent and gives a positive
CD band at 700 nm, shown in Fig. 5B. The weaker binding,
second equivalent of Cu2, is easily removed from PrP causing
a reduction in the negative band at 580 nm and an increase in
the positive Cu(His)2 CD signal at 700 nm. However, even after
twice the required amount of L-His has been added to bind all
of the Cu2 present (8 mol eq relative to PrP-(91–115)) the high
affinity site remains largely unaffected. This is apparent from
the inset in Fig. 5, panel B. The inset compares the CD spec-
trum of Cu2PrP-(91–115) in the presence of 4 eq of L-His with a
spectrum that is a linear combination of Cu1PrP-(91–115) and
Cu(His)2, the spectra are almost identical. A histidine compe-
tition experiment carried out at pH 7.4 has a similar effect. One
and 2 mol eq of histidine relative to Cu2 does not significantly
perturb the Cu1PrP-(91–115) CD bands at 480 and 580 nm.
Only after 8 mol eq of L-His relative to Cu2 do the CD spectra
resemble Cu(His)2.
From these competition studies it is clear that PrP-(91–115)
will bind more than 1 eq of Cu2. The second mole equivalent
of Cu2 will bind to PrP with an affinity comparable with
glycine, whereas the first, higher affinity binding site will
compete successfully for Cu2 in the presence of glycine or even
L-His. A single Cu2 ion, at pH 7.4, binds to PrP-(91–115) with
an affinity slightly greater than to histidine, indicating a nano-
molar dissociation constant for the Cu1PrP-(91–115) complex.
Competition Studies with PrP(4octa)
There has been much interest in copper binding to the oct-
arepeat region of PrP. We have therefore studied the competi-
tive effect of the octarepeat domain (residues 58–91) on Cu2
binding to the PrP-(91–115) fragment. CD was used, as at pH
7.5 the Cu2 d-d absorption bands of PrP-(91–115) differ sig-
nificantly from those of Cu4PrP(4octa) thereby allowing dis-
crimination between copper binding to the two regions of PrP.
Fig. 6A, shows the effect of the addition of apo-PrP-(91–115) to
Cu4PrP(4octa). The characteristic CD bands at 350, 580, and
680 nm (5, 24) are completely lost with the addition of 1 eq of
PrP-(91–115), relative to copper (i.e. sufficient PrP-(91–115) to
bind the four Cu2 ions bound to the octarepeat in a 1:1 com-
plex). The resulting spectrum is almost identical to the spec-
trum shown in Fig. 2B for Cu1PrP-(91–115) at pH 7.5. Inter-
estingly, when half the concentration of PrP-(91–115) is used
the resultant spectrum does not have the appearance of
Cu2PrP-(91–115). In this situation some of the copper is re-
tained by PrP(4octa). This is more clearly observed when the
reverse experiment is performed as shown in Fig. 6B. In this
case an initial spectrum of Cu2PrP-(91–115) is obtained and
subsequent additions of PrP(4octa) remove some (but not all) of
the copper from the lower affinity site of PrP-(91–115). The
resulting spectrum in Fig. 6B most closely resembles a mixture
FIG. 5. Cu2 affinity for PrP-(91–115) from glycine and L-histi-
dine competition, monitored by visible CD. Panel A, Cu2PrP-(91–
115) and glycine competition. Dashed lines show 1 and 2 mol eq of Cu2
added to 0.16 mM PrP-(91–115), pH 9.2. The spectra after each addition
of glycine are shown with solid lines. Spectra corresponding to 2, 8, and
21 mol eq of glycine relative to Cu2 are highlighted. Panel B, Cu2PrP-
(91–115) and L-histidine competition. Solid lines show 1 and 2 mol eq of
Cu2 added to 0.21 mM PrP-(91–115), pH 9.2. The dashed line shows the
spectra obtained after the addition of 8 mol eq of L-histidine (relative to
Cu2). The dotted line shows the spectrum of Cu(His)2. The inset shows
the spectrum of Cu2PrP-(91–115) (dashed line) in the presence of 4 mol
eq of L-histidine compared with a spectrum that is a linear addition of
Cu-PrP-(91–115) and Cu(His)2 (solid line).
FIG. 6. CD monitoring of the Cu2 competition between PrP-
(91–115) and the octarepeat region, PrP(4octa), pH 7.5. Panel A,
solid line is 0.05 mM PrP(4octa) fully loaded with 4 mol eq of Cu2. The
dashed line shows the spectrum obtained after the addition of 0.2 mM
PrP-(91–115). Panel B, solid line is the spectrum of 0.1 mM PrP-(91–
115) loaded with 2 mol eq of Cu2. The dashed line is the spectrum
obtained after the addition of 0.05 mM PrP(4octa).
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of approximately Cu1.5PrP-(91–115) superimposed on a spec-
trum of Cu1.5-PrP(4octa). We have recently shown that glycine
will compete for Cu2 ions bound to PrP(4octa) (24). This is in
agreement with this study, which shows that two copper ions
bind to PrP-(91–115) with a comparable or a greater affinity
than glycine. Fig. 6 gives clear evidence that a single Cu2 ion
will preferentially bind to PrP-(91–115) rather than the octare-
peat region
Cu2 Binding to Full-length PrP Indicates PrP-(91–115)
Is a Good Model for Binding to Full-length PrP
So far we have presented pH dependence and glycine com-
petition data for the PrP fragment, residues 91–115. In Fig. 7
we present data for PrP(23–23151–90). Full-length PrP-(23–
231) is sparingly soluble at pH 6 and above, however, a con-
struct in which the octarepeats have been removed improves
the solubility of the protein between pH 6 and 7.7. This con-
struct contains residues 90–231 necessary for prion propaga-
tion with additional N-terminal residues 23–50.
Visible CD spectra shown in Fig. 7 indicate that PrP-(91–115)
is a good model for Cu2 binding to full-length PrP. Fig. 7A shows
pH dependence of 2 mol eq of copper binding to PrP(23–23151–
90). The visible CD spectra show a close resemblance to Cu2PrP-
(91–115) over the pH range 6.6–7.7. A strong negative band is
observed at 600 nm, pH 6.6, which becomes more negative and
shifts to 620 nm, pH 7.7. The same band is observed for Cu2PrP-
(91–115) with a similar wavelength and intensity of the CD band.
We note there is some variability in the CD bands for Cu2PrP-
(91–115) between 700 and 800 nm, because of baseline instabil-
ity, but the d-d band at 580–600 nm is very consistent between
peptide samples and PrP(23–23151–90).
Fig. 7B shows the effect of glycine competition on Cu2
binding to PrP(23–23151–90) at pH 7.6. As with Cu2PrP-(91–
115), glycine can easily abstract the first mole equivalent of
Cu2 from Cu2PrP(23–23151–90). (Note that copper-Gly is
CD silent.) Again, as with the PrP-(91–115) fragment, even
after the addition of 8 mol eq of glycine, relative to the total
amount of Cu2 present, the high affinity Cu2 binding site is
unperturbed by glycine.
Finally, in Fig. 7C we show, as with PrP-(91–115), the 4octa
repeat fragment, PrP-(58–91), does not remove Cu2 from the
high affinity Cu2 binding site at pH 7.5. Fig. 7C indicates a
single Cu2 will preferentially bind to the region between res-
idues 91 and 115, rather than the octarepeats of PrP. The
PrP-(91–115) fragment behaves in an identical fashion to
PrP(23–23151–90).
It is clear from this data presented in Fig. 7 that the PrP-
(91–115) fragment represents a valid model for copper binding
to full-length PrP at physiological pH values. Copper-free full-
length PrP is unstructured between residues 23 and 126, and
as a consequence the small PrP fragment is a good model for
Cu2 binding. Visible CD is very sensitive to coordination ge-
ometry around the copper ion, however, despite this the spectra
of PrP(23–23151–90) show good agreement with Cu1PrP-(91–
115) spectra. In addition, as would be expected, the competition
experiments show that the PrP-(91–115) has the same affinity
for Cu2 as PrP(23–23151–90).
Coordinating Ligands
EPR—X-band EPR was used to investigate the nature of the
groups coordinating the copper ion. EPR spectra of PrP-(91–
115) at pH 6.5, 7.5, and 9.3 with 1 and 2 mol eq of Cu2 are
shown in Fig. 8, A and B. In agreement with our optical data
the EPR spectra indicate a Type II axial geometry, suggesting
a square-planar (tetragonal) arrangement for both 1 and 2 eq of
Cu2 at all pH values. Peisach and Blumberg (61) have shown
that A and g values provide details of the nature of the
FIG. 7. CD spectra of Cu2-PrP(23–23151–90), effect of pH, gly-
cine, and PrP(4octa) competition. Panel A, Cu(II) was added to
PrP(23–23151–90) (0.07 mM) to a stoichiometry of 2 at an initial pH
of 5.4 and the resulting CD spectrum acquired over the 300–800 nm
range. The pH was incrementally increased and the CD spectrum was
obtained at each pH step. Panel B, 1 and 2 (1.8) eq of Cu(II) were
added to PrP(23–23151–91) (0.07 mM, pH 7.6) and the CD spectrum
was acquired at each addition. Increasing amounts of glycine were
added, up to 13.6 mol eq relative to peptide concentration (8 times
Cu(II) concentration) of glycine had been titrated in (dot-dash lines).
Panel C, 1 and 2 eq of Cu(II) were added to PrP(23–23151–91) (0.07
mM, pH 7.5) and the CD spectrum was acquired at each addition. A
stoichiometric amount of PrP(4octa) (for Cu(II)) was added to Cu2-
PrP(23–23151–91) and the resultant spectrum was obtained (dashed
line), then double the stoichiometric amount was added and the CD
spectrum was acquired (dotted line).
FIG. 8. EPR spectra of Cu-PrP-(91–115), effect of pH. Panel A,
0.13 mM copper-PrP-(91–115) with 1 mol eq of Cu2 at pH 6.5, 7.5, and
9.3. Panel B, 0.13 mM PrP-(91–115) at pH 7.5 and 9.3 with 2 mol eq of
Cu2, spectra were recorded at 20 K.
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coordinating atoms. At 1 eq of Cu2 at pH 6.5, a single set of
hyperfine splittings are observed with A and g values of 15.3
millikaisers and 2.27, respectively. From a Peisach-Blumberg
plot (not shown) the EPR spectra are most typical of equatorial
coordination of three nitrogen atoms and one oxygen (3N1O) or
two nitrogen and two oxygen atoms (2N2O). As the pH is raised
a second set of signals are observed. At physiological pH these
signals are quite weak, but when the pH is raised to 9.3 the
second set of signals have comparable intensity. The A and g
values observed at higher pH values are 17.0 millikaisers and
2.22. These values fall slightly below the nitrogen/oxygen type
II values normally observed implying some distortion in the
geometry, but are closest to 3N1O or 4N coordination. Similar
behavior to the 1 eq spectra is observed when a second mole
equivalent of Cu2 is added, an overlapping set of signals with
comparable A and g values and similar pH dependence are
observed. This supports the visible absorption spectrum that
shows a pH dependence shift in maximum from 610 to 540 nm
typical of a change from 3N1O to 4N coordination.
Analysis of the EPR data for PrP-(91–115) over a range of pH
values shows that the peptide binds copper in a Type II coor-
dination geometry, containing N and O ligands. The EPR spec-
tra presented here for PrP-(91–115) gives g values of 2.2,
which excludes the involvement of sulfur. Based on the ob-
served A and g values, the possibility of equatorial coordina-
tion via a sulfur ligation from (for example) Met112 is unlikely.
Temperature dependence of the EPR spectra was investi-
gated to determine whether there is electron coupling between
the Cu2 ions. The overall appearance and line shape of the
spectra is relatively unaffected by raising the temperature
from 20 to 100 K (data not shown). The lack of temperature
dependence in the spectra indicates that histidine bridging
between two copper ions, as is seen in Cu2 superoxide dis-
mutase complex, is unlikely (62).
1H NMR—The effects of Cu2 on the 1H NMR spectrum of
PrP-(91–115) peptides were studied to determine the nature of
the copper binding site. TOCSY and NOESY were used to fully
assign proton resonances in the apo-PrP-(91–115) spectrum at
pH values ranging from pH 6.5 to 9.3 (see Supplementary
Materials for 1H NMR assignments). Fig. 9 shows that at 0.2
mol eq of Cu2, pH 7.5, proton resonances corresponding to
histidine H, H-1, and H-2 for both His96 and His111 are
broadened significantly more than other resonances. Further-
more, His96 and His111 are broadened to an equal extent upon
Cu2 addition. The -CH3 group of Met
112 also shows specific
broadening.
The electron spin relaxation from the paramagnetic Cu2
resulted in marked broadening of proton NMR resonances
linked to the paramagnetic centers by through-bond (contact)
or through-space (typically 7 Å) (pseudocontact) interactions.
The low levels of Cu2 used (0.2 mol eq) enable the observation
of significant differential broadening of the resonances of pro-
tons close to the copper binding site. The 1H NMR spectra
suggest that the imidazole groups of both His111 and His96 are
involved in coordination of the Cu2. Based on EPR data the
broadening of the CH3 group of Met
112 is most likely because
of this group being close in space to His111 and the paramag-
netic ion rather than directly coordinated.
Analogues PrP(H96A) and PrP(H111A) Indicate a Single
Cu2 Ion Coordinates to Both His96 and His111
In an attempt to further identify the residues involved in
Cu2 binding to PrP-(91–115), two mutants were synthesized
with His96 and His111 replaced with an alanine residue. Fig. 10,
panels A and B, shows the CD spectra in the visible region of
PrP(H111A) and PrP(H96A), respectively. Spectra are shown
with 1 mol eq of Cu2 added. Both PrP(H96A) and PrP(H111A)
give spectra very different from that observed for the wild type
fragment after 1 eq of copper, pH 7.6. Weighted combinations of
the visible CD spectra for PrP(H96A) and PrP(H111A) also
bear no similarity to that PrP-(91–115) spectra. We also note
that that position and sign of the visible CD bands for the two
analogues are pH independent between pH 7 and 9; unlike the
spectra of PrP-(91–115) as shown in Fig. 2, this data is clear
evidence that the first, high affinity copper site requires the
presence of both His96 and His111 residues to form a complex.
To gauge the affinity of copper for the two analogues, free
glycine was added at pH 7.6. The peptide containing His111
only, PrP(H96A), was perturbed by the presence of glycine
(with a 25% loss of intensity) as shown in Fig. 10B. The peptide
containing only His96, PrP(H111A), binds copper even more
weakly. A little over half of the copper is removed from
FIG. 9. 1H NMR spectra of PrP-(91–115) at pH 7.5, 0.34 mM. The
spectra are divided into the aromatic (8.0–6.8 ppm), and part of the
aliphatic region (3.4–2.8 ppm). The lower spectrum (A) corresponds to
apo-PrP-(91–115), whereas the upper spectrum (B) corresponds to PrP-
(91–115) with 0.2 mol eq of Cu2 titrated in. * highlights the H- and †
highlights the H- protons of the histidine imidazole side chain. uphighlights the signals of the histidine H- protons.
FIG. 10. Visible CD spectra of copper-PrP analogues
PrP(H111A) and PrP(H96A). Panel A, 0.19 mM PrP(H111A), pH 7.6,
with 1 mol eq of Cu2 (solid line) and the spectrum obtained after the
addition of 2 mol eq of glycine (dashed line). The decrease in absorption
at 600 nm is 67%. Panel B, spectrum of 0.14 mM PrP(H96A), pH 7.7,
with 1 mol eq of Cu2 (solid line) and the spectrum obtained after the
addition of 2 mol eq of glycine (dashed line). The decrease in absorption
at 500 nm is 25%.
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PrP(H111A) (67%), indicating that Cu2 binds with a compa-
rable affinity to that of glycine. The glycine competition exper-
iments indicate that both PrP(H111A) and PrP(H96A) have an
affinity for Cu2 considerably less than PrP-(91–115) (2 to 3
orders of magnitude less) supporting our assertion that Cu2
requires both His96 and His111 residues to form a complex.
We note that the visible CD spectra for PrP(H96A) and
PrP(H111A) are almost mirror images of each other. Visible
absorption bands for both analogues are centered at 580 nm
with the sign of the CD bands inverted. The hexadecant rule
can be used to interpret CD bands in terms of coordination
geometry around the metal center (59). The sign of the CD band
indicates the position of the side chain relative to the Cu2
coordination plane, and from this it is clear that the position of
the ligands are inverted. This possibly reflects amide coordina-
tion to the residues N terminus of His96 and to the C terminus
of His111. The CD of Cu1PrP(H111A) is almost identical to
spectra of a model peptide Cu1GGGH (N-terminal acetylated)
recently reported (63). This supports our assertion that binding
of copper to PrP(H111A) is via the imidazole ring of His96 and
main chain amide nitrogen to the N terminus of His96.
In summary, we have presented compelling evidence that
the higher affinity site is a complex that requires both His111
and His96. These observations are summarized in Fig. 11.
DISCUSSION
It is now generally accepted that under physiological condi-
tions each of the four histidine-containing octarepeats binds a
single Cu2 ion (24, 25). In addition, another copper ion has
been suggested to bind to a so-called “fifth site” on PrP (4, 21,
64). His96 and/or His111 have been implicated in copper coordi-
nation (22, 28, 29). We have shown that PrP(23–23151–90)
and PrP-(91–115) bind a single Cu2 ion more tightly than the
octarepeat region. Competition studies indicate that residues
between 91 and 115 can remove copper from the four-octare-
peat peptide. A second mole equivalent of copper binds to
PrP-(91–115) with a comparable affinity to the octarepeats.
The solubility of full-length PrP at pH values where Cu2
can bind is low, making spectroscopic studies of full-length PrP
difficult. A construct in which residues 51–90 have been de-
leted from PrP-(23–231) has improved solubility. It is clear that
between pH 6.6 and 7.7, PrP(23–23151–90) binds to Cu2 in
an identical manner to the fragment PrP-(91–115). High affin-
ity Cu2 binding to PrP outside of the octarepeat region ex-
plains why it is possible to purify PrP(23–23151–90) using a
copper affinity column. We have previously reported Cu2-
bound visible CD spectra for full-length PrP (5). The spectra
were obtained with excess Cu2 (25 mol eq) and as a conse-
quence the spectra are dominated by signals from the octare-
peats and signals from the high affinity site only were not
apparent. EPR studies of copper-bound full-length PrP support
the observation that copper binds to the PrP-(91–115) fragment
in an identical fashion to the full-length protein (29).
Copper binding in the 91–115 region has been suggested to
have a femtomolar affinity (22). Our work suggests a more
modest nanomolar dissociation constant, although this is con-
siderably higher than the micromolar dissociation constant
suggested by Kramer et al. (4, 21). The concentration of extra-
cellular Cu2 is typically 10 M in blood plasma (65). It is
known that a fraction of extracellular Cu2 will bind to L-His in
blood plasma (66). From these experiments it is clear that PrP
has a higher affinity than L-His for Cu2. It is therefore ini-
tially possible that extracellular PrP will bind Cu2 under
physiological conditions. The affinity of PrP for copper supports
the in vivo studies showing that PrP binds extracellular
Cu2 (4).
Based on very strong evidence from our visible CD spectra of
PrP(H96A) and PrP(H111A) analogues (Fig. 10), we show that
removal of either His111 or His96 dramatically affects the coor-
dination geometry indicating that both histidines are coordi-
nating ligands to the single high affinity Cu2 site. In contrast,
a recent EPR study of PrP-(90–116) suggests that the higher
Cu2 affinity site binds only a single histidine (His96) and 3
amide main chain nitrogens to the N terminus of His96. We
believe that our data is compelling for both His96 and His111
binding a single Cu2 ion. If only His96 were coordinating the
Cu2 ion, as suggested by Burns et al. (29), PrP-(91–115) visi-
ble CD spectra would have the same appearance at our ana-
logue PrP(H111A), which gives a very characteristic CD spec-
tra for coordination via the imidazole ring and three preceding
amide nitrogens. Furthermore, the affinity of Cu2 for PrP(23–
23151–90) and PrP-(91–115) for Cu2 are 2 orders of magni-
tude higher than would be expected for a single imidazole ring
and amide main chain coordination. We presume that the EPR
study (29) missed this fundamental difference in the complex
because after removal of His111 a square-planar N/O complex
was still formed, although with very different coordination
ligands. In this situation, visible CD spectra are much more
sensitive to a change in ligands.
In addition to the EPR study of the so-called fifth Cu2
binding site, EXAFS has been used to study copper-PrP-(90–
231) (28). EXAFS is a very powerful technique for determining
ligand distance from a metal center. However, it is incapable of
distinguishing square-planar from tetrahedral coordination
and in addition, the scattering difference between N and O
ligands is slight. For these reasons, without supporting data,
EXAFS can at best only suggest the type of coordination. In
addition the EXAFS data were obtained at physiological pH, a
pH at which we have shown that more than one coordination
species is present. This mixture of species will compromise
fitting EXAFS data. Taking on board these caveats, the EXAFS
study supports our observations that copper coordinates to
both His111 and His96 (28).
FIG. 11. Model of PrP-(57–231) showing binding positions of
Cu2 ions. The copper ligating histidine residues are highlighted and
the copper ions are shown as spheres. Distance geometry (Dyana) was
used to incorporate a single copper ion at 2 Å from the N- atoms of
His96 and His111. In addition, each HGGGW Cu2 binding motif in the
octarepeat region was similarly modeled using the crystal structure as
a guide (26). The structured region PrP-(121–231) is from James et al.
(16). Protein Data Bank accession code is 1B1O.
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The EXAFS study of PrP-(90–231) (28) suggests nitrogen
and oxygen ligands at 1.98 Å. Further out at 3.1 Å, the presence
of a sulfur atom improved the EXAFS fit, implicating the in-
volvement of Met112 in coordination. Our 1H NMR data indi-
cates a paramagnetic broadening of the resonance correspond-
ing to the Met112 -CH3 group on addition of Cu
2. The sulfur
atom may be close to the copper center (7 Å) but any direct
coordination to the copper must be an axial, long range inter-
action, on the basis of our EPR data. Indeed, weakly bound
distant ligands axial to the coordination plane generally play
only a minor role in magnetic and optical properties of Cu2
complexes (61). We note that His96 and His111 are conserved in
all mammalian species, whereas Met112 is not (67). The scat-
tering at 3.1 Å assigned to a Met sulfur ligand is not completely
ruled out by our study, but at 3.1 Å from the Cu2 ion it cannot
be a key coordinating ligand. Reliable fitting of attenuated
EXAFS signal at 3 Å is difficult, in addition the presence of
imidazole groups as scatterers will complicate the fitting.
There have also been some spectroscopic studies on Cu(II)
binding to the neurotoxic fragment PrP-(106–126) (39, 68).
However, the peptide fragment studied did not have its N
terminus acetylated, and is therefore not a good model for this
unstructured region of the full-length PrP as Cu2 will coordi-
nate to the N-terminal amino group at position 106. Cu2
coordination to the N-terminal amino group of PrP-(106–126)
results in very different spectra from acetylated PrP(H96A)
used in this study.
It is clear that copper coordination to PrP is very sensitive to
pH. Cu2 binding and affinity can be modulated by subtle
changes in pH. Cu2 can bind to both the octarepeat region and
PrP-(91–115) region at pH values found in the extracellular
environment. If the protein is endocytosed via acidified vacu-
oles, the pH may drop, Cu2 will be released from the octare-
peat region but could still be retained by the PrP-(91–115)
region at pH 6. The structuring of PrP-(91–115) upon Cu2
binding and subsequent pH-dependent restructuring suggests
that the region involving residues 91–115 could play a role in
signaling endocytosis of PrP. It has been shown that the oct-
arepeat region is essential for copper-mediated endocytosis (7).
Copper binding to the unstructured region outside the octare-
peat domain will play a major role in influencing the biological
properties of the full-length prion protein. Functionally, this
may suggest that the region between the N-terminal octarepeat
domain and the structured C-terminal domain acts as a copper-
dependent “hinge” region. Copper binding to His96/111 could
prepare the octarepeat region for copper binding. Indeed, ex-
tending the octarepeat region to incorporate residues between
90 and 115 significantly enhances the affinity and coopera-
tively of Cu2 binding to the octarepeats (21, 64).
Studies that show residues 23–90 are not required for prion
propagation (30–32) make the link between disease and Cu2
binding to the octarepeat region unlikely. However, residues
90–120 (unstructured in apo-PrPC) have been shown to be vital
for prion propagation (30–32). Preferential binding of Cu2 to
this amyloidogenic region of PrP requires us to re-evaluate the
role of copper in prion misfolding and disease. The presence of a
high affinity Cu2 site will have profound implications on the
copper-loaded structure in this region of PrPC, and can account
for the protease resistance of cellular PrP-(90–231) in vivo (36).
Intriguingly, Cu2-dependent protease profiles correspond to
similar profiles seen in different strains of prion disease (37). For
the first time we have shown that coordination of a single Cu2
ion to both His96 and His111 has a profound influence on the
structuring of this amyloidogenic region inducing a -sheet like
conformation. It is this region of PrP that is thought to be key to
prion misfolding and disease, and our data suggests a possible
role for Cu2 in triggering this misfolding and amyloidogenesis.
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Cu2+ titration of PrP(91-115) in the presence of imidazole.  0.23 mM PrP(91-115)
pH 7.5, in 10 mM imidazole, was titrated with one, two and four mole equivalents
of Cu2+.  The dashed line shows the spectrum obtained for PrP(91-115) pH 7.2 with 
one mole equivalent of Cu2+ added in the absence of imidazole.
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pH6.5, 303K.
8.346  HN     91 GLN
4.291  HA     91
2.125  HB2    91
2.071  HB3    91
2.352  QG     91
8.297  HN     94 GLY
3.986  QA     94
8.067  HN     95 THR
4.267  HA     95
4.159  HB   95
1.151  QG     95
8.539  HN     96 HIS
4.650  HA     96
3.239  HB2    96
3.143  HB3    96
7.228  HD2    96
8.242  HN     97 SER
4.375  HA     97
3.781  HB2    97
3.759  HB3    97
8.433  HN     98 GLN
4.271  HA     98
2.154  QG     98
1.927  HB2    98
7.369  HE21 98
6.815  HE22 98
1.834  HB3    98
8.074  HN     99 TRP
4.289  HA     99
3.292  HB2    99
3.197  HB3    99
7.229  HD1    99
7.586  HE3    99
7.213  HZ3    99
7.121  HZ2    99
7.456  HH2    99
8.093  HN    100 ASP
4.606  HA    100
2.555  QB  100
7.963  HN    101 LYS
4.459  HA    101
1.634  QB  101
1.375  QG    101
1.744  QD    101
4.445  HA    102 PRO
2.296  HB2   102
2.005  HB3   102
1.889  QG    102
3.779  HD2   102
3.602  HD3   102
8.375  HN    103 SER
4.417  HA    103
3.823  QB  103
8.279  HN    104 LYS
4.611  HA    104
4.408  HA    105 PRO
2.293  HB2   105
1.999  HB3   105
1.890  QG    105
3.765  HD2   105
3.601  HD3   105
8.470  HN    106 LYS
4.331  HA    106
1.840  HB2   106
1.757  HB3   106
1.457  QG    106
1.704  QD    106
2.994  QE    106
8.086  HN    107 THR
4.323  HA    107
4.165  HB  107
1.171  QG    107
8.511  HN    108 ASN
2.812  HB2   108
2.772  HB3   108
8.294  HN    109 MET
4.433  HA    109
2.050  HB2   109
1.954  HB3   109
2.560  HG2   109
2.487  HG3   109
8.247  HN    110 LYS
4.232  HA    110
1.718  HB2   110
1.655  HB3   110
1.654  HG3   110
1.374  QG    110
2.975  QE    110
8.474  HN    111 HIS
4.329  HA    111
3.228  HB2   111
3.155  HB3   111
7.269  HD2   111
8.387  HN    112 MET 
4.464  HA    112
1.963  QB  112
2.558  HG2   112
2.490  HG3   112
2.953  QE    112
8.397  HN    113 ALA
4.316  HA    113
1.391  QB  113
8.345  HN    114 GLY
3.932  QA    114
8.136  HN    115 ALA
4.310  HA    115
1.377  QB  115
Christopher E. Jones, Salama R. Abdelraheim, David R. Brown and John H. Viles
the Unstructured Amyloidogenic Region of the Prion Protein
-Sheet Formation inβ Induces 111 and His96 Coordination by His2+Preferential Cu
doi: 10.1074/jbc.M403467200 originally published online May 15, 2004
2004, 279:32018-32027.J. Biol. Chem. 
  
 10.1074/jbc.M403467200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2004/06/01/M403467200.DC1.html
  
 http://www.jbc.org/content/279/31/32018.full.html#ref-list-1
This article cites 64 references, 22 of which can be accessed free at
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
